Six Chinese Pharma Companies, Including Qilu Pharmaceutical, Secure Approval for Avatrombopag Maleate Tablets – a Billion-Dollar Therapeutic Blockbuster

　　【Pharmaceutical Network Industry Dynamics】Thrombocytopenia (TP) is a bleeding disorder with a very high prevalence of TP in patients with chronic liver disease. Avatrombopag Maleate Tablets is a medication used to treat thrombocytopenia and is widely applied in the field of hematology treatment.
 

In recent years, with the advancement of medicinal chemistry and drug delivery technologies, the technology and performance of Avatrombopag Maleate Tablets have significantly improved. Industry experts indicate that modern Avatrombopag Maleate Tablets not only exhibit excellent bioavailability and stability but also enhance therapeutic efficacy and safety through optimized design. Moreover, with the increasing demand for efficient drug delivery and personalized treatment, more products using high-performance materials and stringent quality control have emerged in the market.
 

It is reported that the original research company of Avatrombopag Maleate Tablets is AkaRx, Inc., which received approval from the U.S. Food and Drug Administration (FDA) for marketing in May 2018; in June 2019, the product was launched in the EU through the EMA procedure; in April 2020, it received approval from the National Medical Products Administration to enter the Chinese market under the trade name "Sukexin", has been included in the national medical insurance directory, and completed medical insurance renewal in January 2023.
 

With the increase in clinical demand, the market for Avatrombopag Maleate Tablets has developed rapidly, with sales continuing to grow. Data shows that in recent years, the market for Avatrombopag Maleate Tablets has continued to expand in China. In 2023, sales in China's three major terminals and six major markets exceeded 1 billion yuan, representing a year-on-year increase of 25.44%.
 

In addition, according to the information from the National Medical Products Administration, currently, eight companies in China have received approval for the marketing of Avatrombopag Maleate Tablets. Since 2024, six domestic pharmaceutical companies, including Guilin Pharma, Qilu Pharmaceutical, NANJING HENCER PHARMACEUTICAL CO., LTD, BRILLIANT PHARMACEUTICALS, NANJING HEALTHNICE PHARMACEUTICAL CO., LTD, and TIPR PHARMACEUTICAL CO., LTD, have obtained approval for the marketing of Avatrombopag Maleate Tablets.
 

In July this year, the Malate Avatrombopag Tablets developed by TIPR PHARMACEUTICAL CO., LTD received the "Drug Registration Certificate" issued by the National Medical Products Administration, and it was considered to have passed the consistency evaluation. The company stated that the approval of Malate Avatrombopag Tablets will further enrich the preparations product line, optimize the product structure, help the pharmaceutical company continuously deliver high-quality drugs to clinics, and make greater contributions to the development of China's healthcare industry and the health of people's lives.
 

In July, Qilu Pharmaceutical's Avatrombopag Maleate Tablets were also approved for marketing by the National Medical Products Administration (NMPA), indicated for adult patients with chronic liver disease-related thrombocytopenia undergoing scheduled diagnostic procedures or surgery.
 

Data show that Avatrombopag Maleate promotes platelet production by stimulating the proliferation and differentiation of megakaryocytes from bone marrow progenitor cells. It can rapidly increase platelet counts in a short period (3-5 days after treatment) and is suitable for adult patients with chronic liver disease-related thrombocytopenia undergoing elective diagnostic procedures or surgery. Avatrombopag Maleate is safe and well-tolerated, with oral administration not restricted by food type, significantly improving the quality of life for patients with thrombocytopenia. It is an important therapeutic drug for patients with liver cancer complicated by thrombocytopenia.
 

Analysts pointed out that in the future, the development of Avatrombopag Maleate Tablets will focus more on efficiency and multifunctionality. On the one hand, with the application of new material technologies, Avatrombopag Maleate Tablets will adopt more high-performance materials and technologies, such as novel drug carriers and sustained-release technologies, to enhance their bioavailability and therapeutic effects. On the other hand, with the increasing demand for multifunctionality, Avatrombopag Maleate Tablets will develop more products with special functions, such as drugs integrating multiple therapeutic ingredients, to meet the needs of different application scenarios. In addition, with the rising requirements for integration and intelligence in Avatrombopag Maleate Tablets, more products with integrated smart monitoring and automatic control functions will be developed, such as systems with remote monitoring and fault diagnosis capabilities, as well as products with intelligent adjustment features, to adapt to the demands of various application scenarios.